Philip S Low - Net Worth and Insider Trading
Philip S Low Net Worth
The estimated net worth of Philip S Low is at least $12 Million dollars as of 2025-04-16. Philip S Low is the Chief Science Officer of Endocyte Inc and owns about 504,802 shares of Endocyte Inc (ECYT) stock worth over $12 Million. Details can be seen in Philip S Low's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Philip S Low has not made any transactions after 2018-10-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Philip S Low
Philip S Low Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Philip S Low owns 1 companies in total, including Quince Therapeutics Inc (QNCX) .
Click here to see the complete history of Philip S Low’s form 4 insider trades.
Insider Ownership Summary of Philip S Low
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| QNCX | Quince Therapeutics Inc | 2022-05-19 | director |
Philip S Low Latest Holdings Summary
Philip S Low currently owns a total of 1 stock. Philip S Low owns 504,802 shares of Endocyte Inc (ECYT) as of October 5, 2018, with a value of $12 Million.
Latest Holdings of Philip S Low
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ECYT | Endocyte Inc | 2018-10-05 | 504,802 | 23.99 | 12,110,200 |
Holding Weightings of Philip S Low
Philip S Low Form 4 Trading Tracker
According to the SEC Form 4 filings, Philip S Low has made a total of 0 transactions in Endocyte Inc (ECYT) over the past 5 years. The most-recent trade in Endocyte Inc is the sale of 5,928 shares on October 5, 2018, which brought Philip S Low around $92,240.
Insider Trading History of Philip S Low
- 1
Philip S Low Trading Performance
GuruFocus tracks the stock performance after each of Philip S Low's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Philip S Low is 17.44%. GuruFocus also compares Philip S Low's trading performance to market benchmark return within the same time period. The performance of stocks bought by Philip S Low within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Philip S Low's insider trading performs compared to the benchmark.
Performance of Philip S Low
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 6.59 | | | | | |
| Relative Return to S&P 500(%) | 4.07 | | | | | |
Philip S Low Ownership Network
Ownership Network List of Philip S Low
Ownership Network Relation of Philip S Low
Philip S Low Owned Company Details
What does Quince Therapeutics Inc do?
Who are the key executives at Quince Therapeutics Inc?
Philip S Low is the director of Quince Therapeutics Inc. Other key executives at Quince Therapeutics Inc include director & Chief Executive Officer Dirk Thye , Chief Business Officer Brendan Hannah , and President Charles S. Ryan .
Quince Therapeutics Inc (QNCX) Insider Trades Summary
Over the past 18 months, Philip S Low made no insider transaction in Quince Therapeutics Inc (QNCX). Other recent insider transactions involving Quince Therapeutics Inc (QNCX) include a net purchase of 168,384 shares made by David Lamond , a net purchase of 154,500 shares made by Dirk Thye , and a net purchase of 48,387 shares made by Charles S. Ryan .
In summary, during the past 3 months, insiders sold 0 shares of Quince Therapeutics Inc (QNCX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Quince Therapeutics Inc (QNCX) were sold and 410,195 shares were bought by its insiders, resulting in a net purchase of 410,195 shares.
Quince Therapeutics Inc (QNCX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Quince Therapeutics Inc Insider Transactions
Philip S Low Mailing Address
Above is the net worth, insider trading, and ownership report for Philip S Low. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Philip S Low's mailing address is: West Lafayette In 47906.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
